Cargando…

Circulating histone signature of human lean metabolic-associated fatty liver disease (MAFLD)

BACKGROUND: Although metabolic associate fatty liver disease (MAFLD) is associated with obesity, it can also occur in lean patients. MAFLD is more aggressive in lean patients compared to obese patients, with a higher risk of mortality. Specific biomarkers to diagnose differentially lean or overweigh...

Descripción completa

Detalles Bibliográficos
Autores principales: Buzova, Diana, Maugeri, Andrea, Liguori, Antonio, Napodano, Cecilia, Lo Re, Oriana, Oben, Jude, Alisi, Anna, Gasbarrini, Antonio, Grieco, Antonio, Cerveny, Jan, Miele, Luca, Vinciguerra, Manlio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7441674/
https://www.ncbi.nlm.nih.gov/pubmed/32819448
http://dx.doi.org/10.1186/s13148-020-00917-2
_version_ 1783573338990313472
author Buzova, Diana
Maugeri, Andrea
Liguori, Antonio
Napodano, Cecilia
Lo Re, Oriana
Oben, Jude
Alisi, Anna
Gasbarrini, Antonio
Grieco, Antonio
Cerveny, Jan
Miele, Luca
Vinciguerra, Manlio
author_facet Buzova, Diana
Maugeri, Andrea
Liguori, Antonio
Napodano, Cecilia
Lo Re, Oriana
Oben, Jude
Alisi, Anna
Gasbarrini, Antonio
Grieco, Antonio
Cerveny, Jan
Miele, Luca
Vinciguerra, Manlio
author_sort Buzova, Diana
collection PubMed
description BACKGROUND: Although metabolic associate fatty liver disease (MAFLD) is associated with obesity, it can also occur in lean patients. MAFLD is more aggressive in lean patients compared to obese patients, with a higher risk of mortality. Specific biomarkers to diagnose differentially lean or overweight MAFLD are missing. Histones and nucleosomes are released in the bloodstream upon cell death. Here, we propose a new, fast, imaging and epigenetics based approach to investigate the severity of steatosis in lean MAFLD patients. RESULTS: A total of 53 non-obese patients with histologically confirmed diagnosis of MAFLD were recruited. Twenty patients displayed steatosis grade 1 (0–33%), 24 patients with steatosis grade 2 (34–66%) and 9 patients with steatosis grade 3 (67–100%). The levels of circulating nucleosomes were assayed using enzyme-linked immunosorbent assay, while individual histones or histone dimers were assayed in serum samples by means of a new advanced flow cytometry ImageStream(X)-adapted method. Circulating nucleosome levels associated poorly with MAFLD in the absence of obesity. We implemented successfully a multi-channel flow methodology on ImageStream(X), to image single histone staining (H2A, H2B, H3, H4, macroH2A1.1 and macroH2A1.2). We report here a significant depletion of the levels of histone variants macroH2A1.1 and macroH2A1.2 in the serum of lean MAFLD patients, either individually or in complex with H2B. CONCLUSIONS: In summary, we identified a new circulating histone signature able to discriminate the severity of steatosis in individuals with lean MAFLD, using a rapid and non-invasive ImageStream(X)-based imaging technology.
format Online
Article
Text
id pubmed-7441674
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-74416742020-08-24 Circulating histone signature of human lean metabolic-associated fatty liver disease (MAFLD) Buzova, Diana Maugeri, Andrea Liguori, Antonio Napodano, Cecilia Lo Re, Oriana Oben, Jude Alisi, Anna Gasbarrini, Antonio Grieco, Antonio Cerveny, Jan Miele, Luca Vinciguerra, Manlio Clin Epigenetics Research BACKGROUND: Although metabolic associate fatty liver disease (MAFLD) is associated with obesity, it can also occur in lean patients. MAFLD is more aggressive in lean patients compared to obese patients, with a higher risk of mortality. Specific biomarkers to diagnose differentially lean or overweight MAFLD are missing. Histones and nucleosomes are released in the bloodstream upon cell death. Here, we propose a new, fast, imaging and epigenetics based approach to investigate the severity of steatosis in lean MAFLD patients. RESULTS: A total of 53 non-obese patients with histologically confirmed diagnosis of MAFLD were recruited. Twenty patients displayed steatosis grade 1 (0–33%), 24 patients with steatosis grade 2 (34–66%) and 9 patients with steatosis grade 3 (67–100%). The levels of circulating nucleosomes were assayed using enzyme-linked immunosorbent assay, while individual histones or histone dimers were assayed in serum samples by means of a new advanced flow cytometry ImageStream(X)-adapted method. Circulating nucleosome levels associated poorly with MAFLD in the absence of obesity. We implemented successfully a multi-channel flow methodology on ImageStream(X), to image single histone staining (H2A, H2B, H3, H4, macroH2A1.1 and macroH2A1.2). We report here a significant depletion of the levels of histone variants macroH2A1.1 and macroH2A1.2 in the serum of lean MAFLD patients, either individually or in complex with H2B. CONCLUSIONS: In summary, we identified a new circulating histone signature able to discriminate the severity of steatosis in individuals with lean MAFLD, using a rapid and non-invasive ImageStream(X)-based imaging technology. BioMed Central 2020-08-20 /pmc/articles/PMC7441674/ /pubmed/32819448 http://dx.doi.org/10.1186/s13148-020-00917-2 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Buzova, Diana
Maugeri, Andrea
Liguori, Antonio
Napodano, Cecilia
Lo Re, Oriana
Oben, Jude
Alisi, Anna
Gasbarrini, Antonio
Grieco, Antonio
Cerveny, Jan
Miele, Luca
Vinciguerra, Manlio
Circulating histone signature of human lean metabolic-associated fatty liver disease (MAFLD)
title Circulating histone signature of human lean metabolic-associated fatty liver disease (MAFLD)
title_full Circulating histone signature of human lean metabolic-associated fatty liver disease (MAFLD)
title_fullStr Circulating histone signature of human lean metabolic-associated fatty liver disease (MAFLD)
title_full_unstemmed Circulating histone signature of human lean metabolic-associated fatty liver disease (MAFLD)
title_short Circulating histone signature of human lean metabolic-associated fatty liver disease (MAFLD)
title_sort circulating histone signature of human lean metabolic-associated fatty liver disease (mafld)
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7441674/
https://www.ncbi.nlm.nih.gov/pubmed/32819448
http://dx.doi.org/10.1186/s13148-020-00917-2
work_keys_str_mv AT buzovadiana circulatinghistonesignatureofhumanleanmetabolicassociatedfattyliverdiseasemafld
AT maugeriandrea circulatinghistonesignatureofhumanleanmetabolicassociatedfattyliverdiseasemafld
AT liguoriantonio circulatinghistonesignatureofhumanleanmetabolicassociatedfattyliverdiseasemafld
AT napodanocecilia circulatinghistonesignatureofhumanleanmetabolicassociatedfattyliverdiseasemafld
AT loreoriana circulatinghistonesignatureofhumanleanmetabolicassociatedfattyliverdiseasemafld
AT obenjude circulatinghistonesignatureofhumanleanmetabolicassociatedfattyliverdiseasemafld
AT alisianna circulatinghistonesignatureofhumanleanmetabolicassociatedfattyliverdiseasemafld
AT gasbarriniantonio circulatinghistonesignatureofhumanleanmetabolicassociatedfattyliverdiseasemafld
AT griecoantonio circulatinghistonesignatureofhumanleanmetabolicassociatedfattyliverdiseasemafld
AT cervenyjan circulatinghistonesignatureofhumanleanmetabolicassociatedfattyliverdiseasemafld
AT mieleluca circulatinghistonesignatureofhumanleanmetabolicassociatedfattyliverdiseasemafld
AT vinciguerramanlio circulatinghistonesignatureofhumanleanmetabolicassociatedfattyliverdiseasemafld